Modality.AI’s Post

I spent last week in beautiful Stockholm at #ENCALS2024 with 800 colleagues who are working to find a cure for ALS/MND. Here are some key takeaways: 💡 Qalsody (tofersen) is a game changer for so many individuals living with ALS who have a SOD1 mutation, but access is an ongoing challenge. The clinical trial participants will continue to have access, but are concerned the treatment won't be available for their family members and children, who also carry the gene. 💡 There is a big debate about whether precision medicine targets or cocktails are the future of ALS treatment. The conclusion? ~20% of individuals with ALS have a known biomarker, which means 80% of individuals are living with sporadic disease. Targeted treatments are great when we know what we are targeting, but there is still a lot of work to do to identify the targets. Cocktails may give providers more "shots on goal" until we do. 💡 The winner of the best rapid-fire presentation was a researcher looking at the link between head trauma and ALS. Next up? Nexus hosted by The ALS Association in July. If you are attending, I'd love to connect.

A new partnership between UCLH and Guilford Street Laboratories (GSL) will combine next generation testing, artificial intelligence, advanced mass spectrometry and machine learning to diagnostics in the UK.  The partnership, a UK first for the NHS, will marry scientists and clinicians to create new tests meaning earlier diagnoses, better monitoring of new therapies and improved outcomes for NHS patients.  Dr Caitriona O'Rourke, Senior Business Manager, UCLB, said: “It’s inspiring to see such rapid action from GSL, which is combining advanced techniques to improve diagnostics. This strategic partnership will bring hope to many, allowing for faster treatment for diseases including Parkinson’s.”  📖 Read more: https://lnkd.in/eVYt96AJ

🎉 I am excited to share that our paper, “Harnessing Remote Speech Tasks for Early ALS Biomarker Identification,” won the Best Paper Award at IEEE ICDH 2024! 🎉 Our research focuses on improving early diagnosis and understanding of ALS by analyzing speech recordings from 291 participants, including 135 with ALS. Using OpenSMILE to extract acoustic features, we achieved significant results in identifying different stages of ALS. This work represents a crucial step toward reliable biomarkers for ALS, offering new insights into early detection and disease progression. #ALS #IBM #IBMResearch #DigitalHealth

The World CB & CDx Summit in Boston is off to a great start! Swing by Booth 22 to visit our team and say hello! 👋 And be sure to catch Azad Gucwa, Ph.D., MT(ASCP) tomorrow at 2:20p ET, she'll be presenting on: ✅ Leveraging single-cell multi-modal analysis to get a more comprehensive view of multiple myeloma disease progression, therapy response and resistance, and therapy safety & efficacy ✅ Integrating SNVs, zygosity, CNVs, VDJ clonotype, and surface immunophenotype at the single-cell level, while measuring the transduction efficiency and vector copy number of potential CAR-T therapies ✅ Assessing genome integrity through genome-wide CNV analysis at the single-cell level and leverage cohort-level analysis to guide therapeutic and clinical development

The Nordlandssykehuset HF hospital trust in Norway has published a noteworthy paper on the implementation of digital patient monitoring in routine care. The paper emphasizes the importance of addressing barriers and leveraging facilitators, along with utilizing established implementation frameworks, as critical factors for a successful implementation. For more insights, you can access the full paper at the following link: https://lnkd.in/d6ahAyQy.

🗓 Save the Date: December 17th Join us for our upcoming webinar as we explore the achievements, innovations, and real-world clinical benefits of RetinAI Discovery®. We are honored to host esteemed experts, Prof. Paulo Eduardo Stanga and Dr. Francisco Cabrera López, who will share their insights and experiences. What to Expect: 1️⃣ Highlights of RetinAI’s 2024 achievements 2️⃣ A sneak peek at exciting new features to RetinAI Discovery, including: - Automated data uploads to simplify data management - Our AI-powered SEARCH engine for faster patient identification based on biomarker criteria - SMART Alarm Notifications to flag key patient characteristics for efficient monitoring 3️⃣ Real-world insights from physicians using RetinAI Discovery® Join us to see how RetinAI Discovery® is transforming retinal disease management with cutting-edge tools for OCT analysis, fluid tracking, and multimodal data integration. Register now 👉 https://lnkd.in/eQvcsP_D

We want to invite you to join us for an upcoming live webinar: Mobile Visits in an Interstitial Lung Disease Study: A PI’s Perspective During this discussion, we will examine the practical application and benefits of mobile visits in decentralized clinical trials (DCTs) through the eyes of a leading PI actively managing a randomized study on Interstitial Lung Disease. Dr. Rohit Aggarwal, Principal Investigator of the Myositis Interstitial Lung Disease Nintedanib Trial (MINT) at the University of Pittsburgh will be joined by key members of the study implementation team to discuss the challenges and successes of bringing clinical trials directly to patients’ homes. Attendees will: * Understand the practical applications and benefits of mobile visits. * Hear directly from the study team about their experiences incorporating mobile visits into the design and execution of an interstitial lung disease study. * Identify common challenges faced by PIs, study coordinators, and project managers when adopting DCTs and the innovative solutions used to overcome these hurdles. * Obtain practical advice for academic centers and researchers considering decentralized trial designs. This live webinar will take place on Tuesday, August 27, 2024, at 10:00 am EDT.    Register here: https://lnkd.in/g__XBiwT #MobileVisits #PatientCentricity #ClinicalTrials #ClinicalResearch

Is #FHIR something you can relate to in real life? I just watched a great webinar my colleagues organized this week, starting with a presentation from IKNL (Integraal Kankercentrum Nederland): the Dutch knowledge institute aiming to reduce the impact of cancer. Melle Sieswerda mentioned "510 persons are registered in our data every day. With an aging population, you can imagine our data solution needs to be able to scale." I understand that - especially in a webinar focused on FHIR and technology - this is the challenge that's focused on. But what if we pause for a moment with the first 2 words: 510 persons. That's massive, and sad, and... reality. Continuing the presentation, Melle mentioned that data in electronic healthcare records (aka hospital systems) is an important source. And at the moment almost 125 (!) highly educated people are manually extracting those data from hospital systems. A bit later in the webinar, our CEO Rien Wertheim explains that FHIR is built on technologies (like REST API). that underpin many websites and apps that we are all using in our daily lives (think travel websites, banking, eCommerce). If you're not working in healthcare IT yourself, it is hard to imagine why these technologies have not been globally adopted a long time ago. Trust me, it's complicated. But gladly, adoption is increasing. Melle showed some great initiatives in how he is now using FHIR to get access to the cancer data he needs, in a scalable and automated way. So how does FHIR impact real life? It makes data more available. With that data, we can hopefully find ways to improve healthcare for the 510 persons being registered in the cancer registry database every day, or in real life words: being diagnosed with cancer. Want to know more? Check out the full recording and the slides at https://lnkd.in/e2WXdAE2 PS: the marketer in me wants to add that it's all freely available. You don't need to leave your data, no forms are to be submitted. Just go there and watch 🤩 Thanks Ward Weistra for facilitating the webinar. Thanks Melle Sieswerda, Rien Wertheim and Antje Niedostatek for your presentations. Firely - #bringFHIRtolife

📅 🌐 International Day of Radiology!    “Today is the International Day of Radiology! It is a great day to raise awareness of the importance of low-dose CT lung cancer screening for Europe’s population at risk. It also allows us to celebrate the key role radiologists play in this multidisciplinary team effort. It is great to see how the SOLACE project succeeds in setting up implementation pilots, developing science-based guidance for health professionals and decision-makers and in informing Europe’s citizens.”    Monika Hierath, EIBIR Executive Manager, ESR Director of European and International Affairs    SOLACE aims to promote the importance of these life-saving scans and encourage high-risk and hard-to-reach individuals, such as females and people living with comorbidities, to consider screening.    Learn more about the project https://lnkd.in/eukiSx7N  European Health and Digital Executive Agency (HaDEA)    #RespiratoryHealth #IDR2024 #SOLACELUNG #HealthUnion #EUCancerPlan #EU4Health 

We are thrilled to announce that big clinical research of European groups in collaboration with ABCDx will be present at European Stroke Organization Conference in Basel next week 🥂 Several studies will be presented at ESOC using ABCDx technology to demonstrate: 1. The prognostic value of biomarkers measured by a rapid test, FABP and NT proBNP, before thrombectomy is able to identify with high specificity those patients who will have a poor clinical prognosis despite arterial recanalization, which could help in the future to better select which patients receive these treatments or adjuvant treatments.  This will be presented by our CMO Dr Joan Montaner, from the Hospital Macarena and Rocio de Sevilla/IBIS. 2. Dr Ana Barragán, from Hospital Universitario Virgen Macarena, will show how the combination of GFAP and NT proBNP is able to identify with high specificity in the ambulance patients with cerebral haemorrhage in which interventions such as those demonstrated by the interact-3 study could be made to improve their prognosis even before the arrival of these patients to the hospital. This biomarker combination is a technology that ABCDx has licensed exclusively; it presents the results on behalf of the BIOFAST consortium. #ESOC2024 #stroke #strokescience